In order to achieve the purpose, the technical scheme of the invention is as follows: the high-stability reduced glutathione for injection is characterized in that: when the amount of the reduced glutathione is 0.6g, the formula components are as follows: reduced glutathione 0.6g Adjusting the pH of the solution to 6.0-7.0 with 10% sodium hydroxide solution Adding water for injection to 2g When the amount of the reduced glutathione for injection is 1.0g, the formula components are as follows: reduced glutathione 1.0g Adjusting the pH of the solution to 6.0-7.0 with 10% sodium hydroxide solution Adding water for injection to 3.3g When the reduced glutathione for injection is 1.5g, the formula components are as follows: reduced glutathione 1.5g Adjusting the pH of the solution to 6.0-7.0 with 10% sodium hydroxide solution Adding water for injection to 5.0g Wherein, in the liquid preparation process, nitrogen is continuously filled in the liquid preparation and filling processes to keep the oxygen content in the solution below 1.5 ppm
Avoid mega-doses above 2,000mg daily, which increase side effect risk without additional benefit 32 Yin, J
No, Ozempic is not FDA-approved for weight loss, and compounded semaglutide is not FDA-approved for any use, although it may be available during shortages of other FDA-approved semaglutide medications, or when the patient needs a custom dose or formulation that isnt commercially available
doi:10.1001/jama.283.14.1829 O'Connor GT, Caffo B, Newman AB, et al
TGF-1-miR-200a-PTEN induces epithelial-mesenchymal transition and fibrosis of pancreatic stellate cells
